source
- Merck projects continued investment and growth as Keytruda patent expiresMerck reported third‑quarter results on an investor call, saying sales expectations were above forecasts thanks to strong performance of subcutaneous Keytruda and the pulmonary arterial hypertensio…
- Merck and Moderna cancer vaccine data leak shows modest benefit, shares slideA data leak ahead of the European Society of Medical Oncology meeting revealed early results for the personalized cancer vaccine intismeran autogene combined with Merck's Keytruda. The information…